LivaNova PLC (LIVN) stock
Close on Nov 17, 2026Market cap $5.06BP/E 27.1Yield –
LivaNova PLC grew revenue 12.4% to $1.47B over the twelve months to Jun 30, 2026. Operating income rose 6.9% to $187.55M, moving the operating margin from 13.4% to 12.7%. Free cash flow was $148.31M, down 8.5% from a year earlier. At the latest close the market valued the company at $5.06B, 27.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.06B
- P/E ratio
- 27.1
- Price to sales
- 3.44
- Price to book
- 3.82
- Dividend yield
- –
- Free cash flow yield
- 2.93%
Fundamentals
- Revenue
- $1.47B
- Net income
- $188.55M
- EPS, diluted
- $3.39
- Free cash flow
- $148.31M
- Book value per share
- $23.55
- Diluted shares
- 56M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $92.44
- Open
- $92.72
- Day's range
- $91.63 – $93.64
- Volume
- 573,618
- Average volume (20 days)
- 782,874
- 52-week range
- $52.37 – $99.38
- RSI (14 days)
- 65.6
- Volatility (1 year)
- 39.1%
- Relative volume
- 0.85×
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | LIVN | S&P 500 | Difference | LIVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +18.5% | -4.0% | +22.5 pts | ||
| 3 months | +12.8% | -5.0% | +17.8 pts | ||
| Year to date | +49.4% | +8.2% | +41.1 pts | ||
| 1 year | +71.4% | +11.2% | +60.1 pts | ||
| 3 years | +96.5% | +68.5% | +28.1 pts | +25.3% | +19.0% |
| 5 years | +6.9% | +67.3% | −60.3 pts | +1.3% | +10.8% |
| 10 years | +112.6% | +291.6% | −179.1 pts | +7.8% | +14.6% |
Thirteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases LivaNova filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About LivaNova
Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company that designs, develops, manufactures, and markets medical devices, therapies, and related services. The company operates through two primary segments: Cardiopulmonary and Neuromodulation. Its Cardiopulmonary portfolio includes heart-lung machines, oxygenators, autotransfusion systems, cannulae, and perfusion tubing systems utilized during cardiac surgeries. The Neuromodulation business offers vagus nerve stimulation therapy systems for treating drug-resistant epilepsy and difficult-to-treat depression, along with an implantable neurostimulation system under development for obstructive sleep apnea. LivaNova provides its products to hospitals, medical institutions, and healthcare professionals such as perfusionists, neurologists, and neurosurgeons.
Company profile, executives and historyLivaNova stock: common questions
What is LivaNova's stock price?
LIVN closed at $91.92 on Nov 17, 2026, down 0.56% on the day. Over the past 52 weeks it traded between $52.37 and $99.38.
What is LivaNova's market cap?
LivaNova was worth $5.06B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is LIVN's P/E ratio?
LIVN trades at 27.1 times earnings, based on diluted earnings per share of $3.39 over the twelve months to Jun 30, 2026.
How much revenue does LivaNova make?
LivaNova reported revenue of $1.47B for the twelve months to Jun 30, 2026, up 12.4% from a year earlier.
Does LivaNova pay a dividend?
No. LivaNova has not paid a cash dividend over the last twelve months.
When does LivaNova report earnings next?
LivaNova is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LIVN stock performed over the past year?
Including dividends, LIVN returned +71.4% over the past year, against +11.2% for the S&P 500.
How many LIVN shares are sold short?
6M shares were sold short at the latest FINRA report, 11.60% of the float, or 12.4 days of average trading volume.
Who are LivaNova's competitors?
Companies most similar to LivaNova by business, industry and size include CNMD, ITGR, IART, MMSI, TMDX.
See a number that looks wrong?